Coverage
-
February 15, 2019
The row over Allergan Inc.'s controversial deal to sell patents on the dry-eye drug Restasis to a Mohawk tribe to avoid the Patent Trial and Appeal Board continues, as generic makers on Thursday blasted Allergan's "inappropriate" bid for the Federal Circuit to reconsider its decision upholding the invalidity of its patents.
4 other articles on this case.
View all »